The Weill Cornell Institute of Geriatric Psychiatry is conducting a research study on how brain processes affect emotion regulation, social functioning, and well-being in adults ages 45-70 years old. This study is voluntary and will not influence your regular medical care.
   
   Eligible individuals who agree to participate will take part in:
   • An initial screening interview
   • Clinical interviews
   • Cognitive assessments
   • Self-report questionnaires
   • One MRI scan
   

This study is being conducted to test if injectable, long-acting anti-HIV drugs that are given every month can be used safely and effectively in individuals who are infected with HIV and who have had problems taking daily medications in the past. This study is also being conducted to evaluate how well are these study drugs tolerated.
   

The purpose of this study is to investigate the following:

This clinical trial is to evaluate the experimental (investigational) study drug Volixibat in men or women who have been diagnosed with Cholestatic Pruritus (itching) with Primary Sclerosing Cholangitis (PSC). PSC is a disease of the bile ducts, which carry the digestive bile acid (used by the body to help with digestion) from your liver to your small intestine. In PSC, inflammation causes scars within the bile ducts. These scars make the ducts hard and narrow and gradually cause serious liver damage.

The purpose of PREVENTABLE is to learn if taking a statin could help older adults live well for longer by preventing dementia, disability, or heart disease.
   
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. This study seeks to assess the benefit of statins (Atorvastatin) for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
   

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed).

The purpose of this study is to investigate differences in iron in the brains of subjects with and without beta-amyloid deposition. Iron is an essential mineral in your body, and beta-amyloid is a protein associated with Alzheimer’s disease. Studies suggest that excess iron in the brain may be involved in processes that lead to Alzheimer's disease.

We have developed and validated a non-invasive method to estimate the clearance of cerebrospinal fluid (CSF) from the brain. This study tests the hypothesis that reduced CSF clearance is predictive of a) future amyloid lesions, b) brain atrophy, and c) cognitive decline in healthy elderly adults or those with Mild Cognitive Impairment (MCI). 

 Measuring brain CSF clearance with novel, experimental imaging techniques may advance the understanding of Alzheimer’s disease (AD) progression at its earliest stages. 

This is a clinical trial for adults with cancer, which has continued to grow despite the treatments already received, because the standard drugs used to treat the disease are no longer working, because the tumor cells are resistant to available treatments, or subjects are not a candidate for or intolerant of other available treatments. The subjects with solid tumors and lymphoma are eligible for this trial.
   

The purpose of this study is to assess the efficacy of this combination of drugs in light chain (AL) amyloidosis which has relapsed or become refractory to other treatments. Amyloidosis is a rare disease that is caused by a substance called amyloid. Amyloid is an abnormal protein produced by plasma cells in the bone marrow which cannot be broken down by the body and so accumulate over time in various organs. Amyloidosis can affect different organs in different people. The most commonly affected organs are the heart, kidney, liver, spleen, nervous system, and digestive tract.